Developing new antibiotics targeting specific bacterial enzymes
Synthesis and Evaluation of Prp-Specific Probes and Prodrugs
['FUNDING_R21'] · VIRGINIA COMMONWEALTH UNIVERSITY · NIH-10742524
This study is working on new antibiotics that can specifically target harmful bacteria like Staphylococcus aureus and Clostridioides difficile, while leaving good bacteria alone, to help fight infections more effectively.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VIRGINIA COMMONWEALTH UNIVERSITY (nih funded) |
| Locations | 1 site (RICHMOND, UNITED STATES) |
| Trial ID | NIH-10742524 on ClinicalTrials.gov |
What this research studies
This research focuses on creating new antibiotics that specifically target a unique enzyme called phage-related ribosomal protease (Prp), which is essential for the survival of certain harmful bacteria like Staphylococcus aureus and Clostridioides difficile. By understanding how Prp interacts with ribosomal proteins, the researchers aim to design prodrugs that can selectively kill these pathogens while sparing beneficial bacteria. The study will involve testing these new drugs for their effectiveness against both harmful and beneficial bacteria, providing insights into their selectivity and reactivity.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from infections caused by antibiotic-resistant bacteria, such as those caused by Staphylococcus aureus or Clostridioides difficile.
Not a fit: Patients with infections caused by bacteria that do not utilize the Prp enzyme may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective antibiotics that combat antibiotic-resistant infections with fewer side effects.
How similar studies have performed: Previous research has shown promise in targeting specific bacterial enzymes for antibiotic development, indicating that this approach has potential for success.
Where this research is happening
RICHMOND, UNITED STATES
- VIRGINIA COMMONWEALTH UNIVERSITY — RICHMOND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MAY, AARON ELIJAH — VIRGINIA COMMONWEALTH UNIVERSITY
- Study coordinator: MAY, AARON ELIJAH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.